Co-Diagnostics, Inc.

As of March 27, 2025, Co-Diagnostics, Inc. is classified as "does not qualify" due to significant financial deterioration, negative ratios indicating overvaluation, and a year-to-date stock performance of -65.97%, underperforming the S&P 500's 2.44% return.

As of June 2, 2025, the market trend is mildly bearish, indicated by daily moving averages and Bollinger Bands, while weekly MACD and KST suggest a mildly bullish outlook, leading to mixed signals and a cautious stance.

As of March 2022, the management team of Co-Diagnostics, Inc. includes Mr. Dwight Egan as Chairman, President, and CEO, along with independent directors Dr. Eugene Durenard, Mr. Edward Murphy, Mr. James Nelson, and Mr. Richard Serbin.

Co-Diagnostics, Inc. is a molecular diagnostics company focused on developing and marketing diagnostic technologies in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $0 million and a net loss of $8 million, with a market cap of $9.13 million.

As of Jun 18, Co-Diagnostics, Inc. has a market capitalization of 9.13 million, with net sales of 0.57 million and a net profit of -35.86 million over the latest four quarters. The company reported shareholder's funds of 54.31 million and total assets of 71.19 million as of Dec 24.